Early adoption of non‐financial disclosure in family firms
European Management Review · 2025-12 · 22 (4) · 888-909
DOI: 10.1111/emre.12690 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Management Review, online erschienen am 08.10.2024. Verfasst von Maria Angela Manzi und 3 weiteren Autor:innen. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 133 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).
Abstract (Originalsprache)
This study investigates when the reputation enhancing signals of family firms include early adoption of non‐financial disclosure. Drawing on signalling theory, we examine the effect of family ownership on the early adoption of non‐financial disclosure and the moderating role of contingency signals: founder chief executive officer (CEO) leadership and employee degrowth rate. We test our hypotheses with panel regressions on a dataset of Italian listed family firms over the period 2013–2017, years before the introduction of mandatory non‐financial reporting. The results reveal an inverted U‐shaped relationship between family ownership and early adoption of non‐financial disclosure, negatively moderated by the presence of a founder CEO and positively moderated by employee degrowth. We discuss the implications of our findings for theory and practice.
Zitieren
APA
Manzi, M. A., Cirillo, A., Mussolino, D., & Uman, T. (2025). Early adoption of non‐financial disclosure in family firms. European Management Review, 22(4), 888-909. https://doi.org/10.1111/emre.12690
Vancouver
Manzi MA, Cirillo A, Mussolino D, Uman T. Early adoption of non‐financial disclosure in family firms. European Management Review. 2025;22(4):888-909. doi:10.1111/emre.12690
BibTeX
@article{Manzi2025,
author = {Manzi, Maria Angela and Cirillo, Alessandro and Mussolino, Donata and Uman, Timur},
title = {Early adoption of non‐financial disclosure in family firms},
journal = {European Management Review},
year = {2025},
volume = {22},
number = {4},
pages = {888--909},
doi = {10.1111/emre.12690}
}
EUVIMED